Search

The initiative is coming to an end after three years of activity (2022-2024), accompanying the growth of eleven entities in the healthcare sector.

Miramoon Pharma has hit a major milestone with the publication of preclinical data for its two lead candidates in top-tier peer-reviewed journals.

The SEBBM, in collaboration with the Carmen and Severo Ochoa Foundation, launch the Severo Ochoa Conferences, which will deal monographically with research topics on the frontier of knowledge and will

BCN HEALTH has published 10 studies in 2024 that assess the incidence, productivity loss, and cost of disease for different diseases in Spain.

Meet Biointaxis, our new member. We spoke with Antoni Matilla Dueñas CEO, Co-fundador.

Integra Therapeutics has developed the FiCAT gene-writing platform to develop cell therapies for autoimmune and oncology diseases and gene therapies for rare diseases. The company recently announced a

To contribute to the democratization of access to new cell therapies, Klinea works on various initiatives. The project explained below is an example of this commitment.

We trust that this decision will help reduce the bottleneck caused by the high demand for certification under the new regulatory framework and the limited availability of certification capacities

En la Fase de madurez del ciclo de vida de un proyecto es necesario idear estrategias de crecimiento para evitar el declive

Repsol, through its investment arm Repsol Corporate Venturing, has acquired a 21.43% stake in DARWIN Bioprospecting Excellence, a Valencian startup that is a leader in biotechnology, focusing on

Biobide shares its latest research, Safe-and-Sustainable-by-Design Redox Active Molecules for Energy Storage Applications, published in Energy, Sustainability and Society.

BIOSPAIN 2025, taking place from October 7 to 9, aims to match the record-breaking figures of its last edition: more than 2,200 professionals from 34 countries worldwide, over 5,000 one-to-one

The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder